This Note describes the events surrounding the decision by the National Heart and Lung Institute (NHLI) to issue a request for proposal (RFP) to conduct a multicenter randomized clinical trial comparing the efficacy of intermittent positive pressure breathing (IPPB) with compressor nebulizer therapy in treating patients with chronic obstructive pulmonary disease (COPD). The Note describes (1) the disease process associated with COPD and the history of IPPB treatment for this disease; (2) the decisionmaking process that led to NHLI's decision to issue an RFP for the study of IPPB therapy; (3) the motivations of three of the investigators responding to the RFP; and (4) the case study as a model for future decisionmaking.
This report is part of the RAND Corporation Note series. The note was a product of the RAND Corporation from 1979 to 1993 that reported other outputs of sponsored research for general distribution.
Our mission to help improve policy and decisionmaking through research and analysis is enabled through our core values of quality and objectivity and our unwavering commitment to the highest level of integrity and ethical behavior. To help ensure our research and analysis are rigorous, objective, and nonpartisan, we subject our research publications to a robust and exacting quality-assurance process; avoid both the appearance and reality of financial and other conflicts of interest through staff training, project screening, and a policy of mandatory disclosure; and pursue transparency in our research engagements through our commitment to the open publication of our research findings and recommendations, disclosure of the source of funding of published research, and policies to ensure intellectual independence. For more information, visit www.rand.org/about/principles.
The RAND Corporation is a nonprofit institution that helps improve policy and decisionmaking through research and analysis. RAND's publications do not necessarily reflect the opinions of its research clients and sponsors.